HYBRID EVENT: Join us in person in Tokyo, Japan or attend virtually from anywhere.
Esophageal Adenocarcinoma

Esophageal adenocarcinoma is a type of cancer that develops in the cells lining the lower part of the esophagus, the tube that connects the throat to the stomach. This malignancy typically arises from glandular cells and is often associated with a condition called Barrett's esophagus, where the normal squamous epithelium of the esophagus is replaced by intestinal-like cells. The exact cause of esophageal adenocarcinoma is not fully understood, but certain risk factors increase the likelihood of its development. Chronic gastroesophageal reflux disease (GERD) and long-term inflammation of the esophagus are key contributors, as they can lead to changes in the lining of the esophagus over time. Symptoms of esophageal adenocarcinoma may include difficulty swallowing, unintended weight loss, chest pain, and discomfort while eating. Unfortunately, these symptoms often manifest in the later stages of the disease, making early detection challenging. Diagnosis typically involves endoscopic procedures, such as an esophagogastroduodenoscopy (EGD), where a flexible tube with a camera is inserted into the esophagus to examine the tissue. Biopsies may be taken to confirm the presence of cancer cells. Treatment options for esophageal adenocarcinoma depend on the stage of the cancer. Surgery, chemotherapy, and radiation therapy are commonly employed, either individually or in combination. In advanced cases, palliative care may be recommended to manage symptoms and improve the patient's quality of life. Prognosis for esophageal adenocarcinoma is often guarded, especially in advanced stages. Early detection and intervention can significantly improve outcomes, underscoring the importance of regular medical check-ups, especially for individuals with known risk factors. Preventive measures include lifestyle modifications such as maintaining a healthy weight, avoiding tobacco and excessive alcohol consumption, and managing conditions like GERD. Despite ongoing research efforts, esophageal adenocarcinoma remains a formidable challenge in the field of oncology, highlighting the need for increased awareness and improved screening strategies.

Committee Members
Speaker at International Conference on Clinical & Translational Oncology 2026 - Yan Leyfman

Yan Leyfman

NYP- Meyer Cancer Center, United States
Speaker at International Conference on Clinical & Translational Oncology 2026 - Rajvir Dahiya

Rajvir Dahiya

University of California San Francisco, United States
Speaker at International Conference on Clinical & Translational Oncology 2026 - Jianhua Luo

Jianhua Luo

University of Pittsburgh School of Medicine, United States
ICTO 2026 Speakers
Speaker at International Conference on Clinical & Translational Oncology 2026 - Pietro Salvatori

Pietro Salvatori

Formerly, Humanitas San Pio X Hospital, Italy
Speaker at International Conference on Clinical & Translational Oncology 2026 - Sergey Suchkov

Sergey Suchkov

N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Speaker at International Conference on Clinical & Translational Oncology 2026 - Shinya Tajima

Shinya Tajima

National Hospital Organization Shizuoka Medical Centre, Japan
Speaker at International Conference on Clinical & Translational Oncology 2026 - Nayara Delgado Andre

Nayara Delgado Andre

Federal University of São João del-Rei (UFSJ), Brazil
Tags

Submit your abstract Today

Facebook Twitter XTwitter Youtube
Watsapp